trending Market Intelligence /marketintelligence/en/news-insights/trending/UFLpOuKnWhYtqe-qGmbxBQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Stemline Therapeutics to raise $76.3M to commercialize cancer drug Elzonris

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Stemline Therapeutics to raise $76.3M to commercialize cancer drug Elzonris

Stemline Therapeutics Inc. priced an underwritten public offering to raise about $76.3 million.

The New York-based cancer drug developer will sell 5 million shares at $15.25 apiece to raise the amount, which will be used primarily for commercial activities of Elzonris, a treatment for blastic plasmacytoid dendritic cell neoplasm, a rare blood disease.

J.P. Morgan Securities LLC and Cowen and Co. LLC are the joint book-running managers for the offering, while Cantor Fitzgerald & Co., Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co. LLC are acting as co-lead managers. ThinkEquity of Fordham Financial Management Inc., Alliance Global Partners and Aegis Capital Corp. are acting as co-managers for the offering.

The underwriters can purchase up to an additional 750,000 shares from the company. The offering is expected to close on or around Aug. 13.